Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Kelley RK"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-12 z 12
    Tytuł:
    Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve
    Autorzy:
    Fidelman N
    Johanson C
    Kohi MP
    Kolli KP
    Kohlbrenner RM
    Lehrman ED
    Taylor AG
    Kelley RK
    Yao FY
    Roberts JP
    Kerlan RK
    Pokaż więcej
    Temat:
    hepatocellular carcinoma
    chemoembolization
    liver transplantation
    Neoplasms. Tumors. Oncology. Including cancer and carcinogens
    RC254-282
    Źródło:
    Journal of Hepatocellular Carcinoma, Vol Volume 6, Pp 93-103 (2019)
    Opis pliku:
    electronic resource
    Relacje:
    https://www.dovepress.com/prospective-phase-ii-trial-of-drug-eluting-bead-chemoembolization-for--peer-reviewed-article-JHC; https://doaj.org/toc/2253-5969
    Dostęp URL:
    https://doaj.org/article/362d0db33aa84b978c6bcb3ea0066040  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.
    Autorzy:
    El-Khoueiry AB; USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA. .
    Meyer T; Royal Free Hospital, University College London, London, UK.
    Cheng AL; National Taiwan University Hospital, Taipei, Taiwan.
    Rimassa L; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
    Sen S; Exelixis, Inc, Alameda, CA, USA.
    Milwee S; Exelixis, Inc, Alameda, CA, USA.
    Kelley RK; UCSF Helen Diller Family Comprehensive Cancer Center, CA, San Francisco, USA.
    Abou-Alfa GK; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Medical College at Cornell University, New York, NY, USA.
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2022 Apr 09; Vol. 22 (1), pp. 377. Date of Electronic Publication: 2022 Apr 09.
    Typ publikacji:
    Journal Article; Randomized Controlled Trial
    MeSH Terms:
    Antineoplastic Agents*/adverse effects
    Carcinoma, Hepatocellular*/pathology
    Liver Neoplasms*/pathology
    Adult ; Anilides ; Humans ; Liver Cirrhosis/drug therapy ; Prospective Studies ; Pyridines ; Retrospective Studies
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Ignoring Spatial and Spatiotemporal Dependence in the Disturbances Can Make Black Swans Appear Grey.
    Autorzy:
    Pace RK; LREC Endowed Chair of Real Estate, Department of Finance, Louisiana State University, Baton Rouge, LA USA.
    Calabrese R; Associate Professor in Data Science, Credit Research Centre, Business School University of Edinburgh, Edinburgh, Scotland.
    Pokaż więcej
    Źródło:
    The journal of real estate finance and economics [J Real Estate Financ Econ (Dordr)] 2022; Vol. 65 (1), pp. 1-21. Date of Electronic Publication: 2021 Mar 31.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
    Autorzy:
    Giannelli G
    Santoro A
    Kelley RK
    Gane E
    Paradis V
    Cleverly A
    Smith C
    Estrem ST
    Man M
    Wang S
    Lahn MM
    Raymond E
    Benhadji KA
    Faivre S
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2021 Jun 17; Vol. 16 (6), pp. e0253671. Date of Electronic Publication: 2021 Jun 17 (Print Publication: 2021).
    Typ publikacji:
    Published Erratum
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
    Autorzy:
    Harding JJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA.
    Do RK; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA.
    Yaqubie A; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Cleverly A; Elli Lilly and Company, Indianapolis, IN, USA.
    Zhao Y; Elli Lilly and Company, Indianapolis, IN, USA.
    Gueorguieva I; Elli Lilly and Company, Indianapolis, IN, USA.
    Lahn M; Elli Lilly and Company, Indianapolis, IN, USA.
    Benhadji KA; Elli Lilly and Company, Indianapolis, IN, USA.
    Kelley RK; Helen Diller Cancer Center, University of California San Francisco, San Francisco, CA, USA.
    Abou-Alfa GK; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA.
    Pokaż więcej
    Źródło:
    Cancer medicine [Cancer Med] 2021 May; Vol. 10 (9), pp. 3059-3067. Date of Electronic Publication: 2021 Apr 02.
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antibodies, Monoclonal, Humanized/*administration & dosage
    Antineoplastic Agents/*administration & dosage
    Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
    Carcinoma, Hepatocellular/*drug therapy
    Liver Neoplasms/*drug therapy
    Pyrazoles/*administration & dosage
    Quinolines/*administration & dosage
    Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Hepatocellular/metabolism ; Carcinoma, Hepatocellular/pathology ; Female ; Humans ; Liver Neoplasms/metabolism ; Liver Neoplasms/pathology ; Male ; Maximum Tolerated Dose ; Middle Aged ; Nausea/chemically induced ; Prospective Studies ; Pyrazoles/adverse effects ; Pyrazoles/pharmacokinetics ; Quinolines/adverse effects ; Quinolines/pharmacokinetics ; Receptor, Transforming Growth Factor-beta Type I/antagonists & inhibitors ; Response Evaluation Criteria in Solid Tumors ; Vascular Endothelial Growth Factor A/metabolism ; Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors ; Vomiting/chemically induced ; alpha-Fetoproteins/analysis ; Ramucirumab
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Demographic, jurisdictional, and spatial effects on social distancing in the United States during the COVID-19 pandemic.
    Autorzy:
    Narayanan RP; E.J. Ourso College of Business Administration, Louisiana State University, Baton Rouge, Louisiana, United States of America.
    Nordlund J; E.J. Ourso College of Business Administration, Louisiana State University, Baton Rouge, Louisiana, United States of America.
    Pace RK; E.J. Ourso College of Business Administration, Louisiana State University, Baton Rouge, Louisiana, United States of America.
    Ratnadiwakara D; E.J. Ourso College of Business Administration, Louisiana State University, Baton Rouge, Louisiana, United States of America.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2020 Sep 22; Vol. 15 (9), pp. e0239572. Date of Electronic Publication: 2020 Sep 22 (Print Publication: 2020).
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Betacoronavirus*
    Models, Theoretical*
    Psychological Distance*
    Coronavirus Infections/*epidemiology
    Pneumonia, Viral/*epidemiology
    COVID-19 ; Cluster Analysis ; Coronavirus Infections/prevention & control ; Cross-Sectional Studies ; Demography ; Humans ; Local Government ; Pandemics/prevention & control ; Pneumonia, Viral/prevention & control ; SARS-CoV-2 ; Social Isolation ; United States
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
    Autorzy:
    Giannelli G; National Institute of Gastroenterology, 's. De Bellis' Research Hospital, Castellana Grotte, Bari, Italy.
    Santoro A; Humanitas Clinical Institute, Milano, Italy.
    Kelley RK; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, United States of America.
    Gane E; Auckland City Hospital, Auckland, New Zealand.
    Paradis V; Beaujon Hospital, Clichy, France.
    Cleverly A; Eli Lilly and Company, Windlesham, Surrey, United Kingdom.
    Smith C; Eli Lilly and Company, Windlesham, Surrey, United Kingdom.
    Estrem ST; Eli Lilly and Company, Indianapolis, Indiana, United States of America.
    Man M; Eli Lilly and Company, Indianapolis, Indiana, United States of America.
    Wang S; BioStat Solutions, Inc., Frederick, Maryland, United States of America.
    Lahn MM; Eli Lilly and Company, Indianapolis, Indiana, United States of America.
    Raymond E; Paris Saint-Joseph Hospital Center, Paris, France.
    Benhadji KA; Eli Lilly and Company, Indianapolis, Indiana, United States of America.
    Faivre S; Paris Saint-Joseph Hospital Center, Paris, France.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2020 Mar 25; Vol. 15 (3), pp. e0222259. Date of Electronic Publication: 2020 Mar 25 (Print Publication: 2020).
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Carcinoma, Hepatocellular/*drug therapy
    Carcinoma, Hepatocellular/*mortality
    Liver Neoplasms/*drug therapy
    Liver Neoplasms/*mortality
    Pyrazoles/*pharmacology
    Pyrazoles/*therapeutic use
    Quinolines/*pharmacology
    Quinolines/*therapeutic use
    Receptor, Transforming Growth Factor-beta Type I/*antagonists & inhibitors
    Adult ; Aged ; Aged, 80 and over ; Antigens, CD/blood ; Biomarkers, Tumor/blood ; Cadherins/blood ; Carcinoma, Hepatocellular/blood ; Cohort Studies ; Female ; Humans ; Liver Neoplasms/blood ; Male ; MicroRNAs/blood ; Middle Aged ; Prognosis ; Survival Rate ; Transforming Growth Factor beta1/analysis ; Treatment Outcome ; alpha-Fetoproteins/analysis
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
    Autorzy:
    Faivre S; Oncologie Médicale, Hopital Beaujon, Clichy, France.
    Santoro A; Istituto Clinico Humanitas, Humanitas University, Rozzano, Italy.
    Kelley RK; University of California, San Francisco, CA.
    Gane E; Auckland City Hospital, Auckland, New Zealand.
    Costentin CE; Hospital Henri Mondor, Creteil, France.
    Gueorguieva I; Lilly Research Centre Erl Wood Manor, Windlesham, UK.
    Smith C; Lilly Research Centre Erl Wood Manor, Windlesham, UK.
    Cleverly A; Lilly Research Centre Erl Wood Manor, Windlesham, UK.
    Lahn MM; Eli Lilly and Company, Indianapolis, IN.
    Raymond E; Centre Hospitalier Paris Saint-Joseph, Paris, France.
    Benhadji KA; Eli Lilly and Company, Indianapolis, IN.
    Giannelli G; National Institute of Gastroenterology, Research Instituts 'S. De Bellis' Research Hospital, Castellana Grotte, Bari, Italy.
    Pokaż więcej
    Źródło:
    Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2019 Aug; Vol. 39 (8), pp. 1468-1477. Date of Electronic Publication: 2019 Jun 03.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Carcinoma, Hepatocellular/*drug therapy
    Liver Neoplasms/*drug therapy
    Pyrazoles/*therapeutic use
    Quinolines/*therapeutic use
    Receptor, Transforming Growth Factor-beta Type I/*antagonists & inhibitors
    Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Pyrazoles/pharmacology ; Quinolines/pharmacology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Imaging Hepatocellular Carcinoma With Ga-Citrate PET: First Clinical Experience.
    Autorzy:
    Mari Aparici C; 1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
    Behr SC; 1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
    Seo Y; 1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.; 2 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
    Kelley RK; 2 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
    Corvera C; 3 Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
    Gao KT; 1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
    Aggarwal R; 2 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
    Evans MJ; 1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.; 2 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; 4 Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
    Pokaż więcej
    Źródło:
    Molecular imaging [Mol Imaging] 2017 Jan-Dec; Vol. 16, pp. 1536012117723256.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    Positron-Emission Tomography*
    Carcinoma, Hepatocellular/*diagnostic imaging
    Citrates/*chemistry
    Gallium/*chemistry
    Liver Neoplasms/*diagnostic imaging
    Adult ; Carcinoma, Hepatocellular/pathology ; Humans ; Liver/diagnostic imaging ; Liver/pathology ; Liver Neoplasms/pathology ; Male ; Transferrin/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
    Autorzy:
    Kelley RK; Helen Diller Family Comprehensive Cancer Center and The Liver Center, University of California San Francisco (UCSF), 550 16th St., Box 3211, San Francisco, CA, 94143, USA. Katie.kelley@ucsf.edu.
    Magbanua MJ; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, 94143, USA. .
    Butler TM; Department of Molecular and Medical Genetics, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Mail Code #L103, Portland, OR, 97239, USA. .
    Collisson EA; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, 94143, USA. .
    Hwang J; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, 94143, USA. .
    Sidiropoulos N; University of Vermont Medical Center, 89 Beaumont Ave., Burlington, VT, 05405, USA. .
    Evason K; Department of Pathology, UCSF, 513 Parnassus Ave., San Francisco, CA, 94143, USA. .
    McWhirter RM; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, 94143, USA. .
    Hameed B; Division of Hepatology and Liver Transplant, UCSF, 513 Parnassus Ave., S-357, San Francisco, CA, 94143, USA. .
    Wayne EM; Department of Transplantation-Abdominal, UCSF, 513 Parnassus Ave., S-357, San Francisco, CA, 94143, USA. .
    Yao FY; Division of Hepatology and Liver Transplant and The Liver Center, UCSF, 513 Parnassus Ave., S-357, San Francisco, CA, 94143, USA. .
    Venook AP; Helen Diller Family Comprehensive Cancer Center and The Liver Center, University of California San Francisco (UCSF), 550 16th St., Box 3211, San Francisco, CA, 94143, USA. .
    Park JW; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, 94143, USA. .
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2015 Mar 31; Vol. 15, pp. 206. Date of Electronic Publication: 2015 Mar 31.
    Typ publikacji:
    Clinical Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Neoplastic Cells, Circulating*
    Antigens, Neoplasm/*genetics
    Carcinoma, Hepatocellular/*genetics
    Cell Adhesion Molecules/*genetics
    Liver Neoplasms/*genetics
    Aged ; Aged, 80 and over ; Antigens, Neoplasm/blood ; Carcinoma, Hepatocellular/blood ; Carcinoma, Hepatocellular/pathology ; Cell Adhesion Molecules/blood ; Epithelial Cell Adhesion Molecule ; Epithelial-Mesenchymal Transition/genetics ; Female ; High-Throughput Nucleotide Sequencing ; Humans ; Kaplan-Meier Estimate ; Liver Diseases/blood ; Liver Diseases/genetics ; Liver Diseases/pathology ; Liver Neoplasms/blood ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Metastasis ; Polymorphism, Single Nucleotide ; Prognosis
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
    Autorzy:
    Kelley RK; Department of Medicine, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, Box 1700, San Francisco, CA 94143, USA.
    Hwang J
    Magbanua MJ
    Watt L
    Beumer JH
    Christner SM
    Baruchel S
    Wu B
    Fong L
    Yeh BM
    Moore AP
    Ko AH
    Korn WM
    Rajpal S
    Park JW
    Tempero MA
    Venook AP
    Bergsland EK
    Pokaż więcej
    Źródło:
    British journal of cancer [Br J Cancer] 2013 Oct 01; Vol. 109 (7), pp. 1725-34. Date of Electronic Publication: 2013 Sep 10.
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antibodies, Monoclonal, Humanized/*therapeutic use
    Antineoplastic Agents/*therapeutic use
    Benzamides/*therapeutic use
    Colorectal Neoplasms/*drug therapy
    Cyclophosphamide/*therapeutic use
    Piperazines/*therapeutic use
    Pyrimidines/*therapeutic use
    Adult ; Aged ; Angiogenesis Inhibitors/adverse effects ; Angiogenesis Inhibitors/pharmacokinetics ; Angiogenesis Inhibitors/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Benzamides/adverse effects ; Benzamides/pharmacokinetics ; Bevacizumab ; Cyclophosphamide/adverse effects ; Cyclophosphamide/pharmacokinetics ; Drug Administration Schedule ; Female ; Humans ; Imatinib Mesylate ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplastic Cells, Circulating/drug effects ; Piperazines/adverse effects ; Piperazines/pharmacokinetics ; Pyrimidines/adverse effects ; Pyrimidines/pharmacokinetics ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-12 z 12

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies